We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
We are committed to bringing more of our medicines to more people, no matter where they are.
People and Culture
Novartis is building an Inspired, Curious and Unbossed culture.
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
Novartis Financial Results - Q3 2022
Novartis announced the company's financial results for the third quarter of 2022.
Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.
The Novartis Commitment to Patients and Caregivers
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.
Environmental, Social and Governance
We have a responsibility and opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.